The stock price of Travere Therapeutics Inc (NASDAQ: TVTX) has surged by 0.88% when compared to previous closing price of $14.71, but the company has seen a -0.70% decline in its stock price over the last five trading sessions. prnewswire.com reported 2025-07-02 that NEW YORK, July 2, 2025 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. (“Travere” or the “Company”) (NASDAQ: TVTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Is It Worth Investing in Travere Therapeutics Inc (NASDAQ: TVTX) Right Now?
The stock has a 36-month beta value of 0.75. Opinions on the stock are mixed, with 11 analysts rating it as a “buy,” 3 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for TVTX is 87.50M, and at present, short sellers hold a 11.80% of that float. On July 03, 2025, the average trading volume of TVTX was 1.77M shares.
TVTX’s Market Performance
TVTX stock saw a decrease of -0.70% in the past week, with a monthly decline of -4.38% and a quarterly a decrease of -14.91%. The volatility ratio for the week is 4.01%, and the volatility levels for the last 30 days are 4.66% for Travere Therapeutics Inc (TVTX). The simple moving average for the last 20 days is 0.38% for TVTX stock, with a simple moving average of -17.10% for the last 200 days.
Analysts’ Opinion of TVTX
Many brokerage firms have already submitted their reports for TVTX stocks, with H.C. Wainwright repeating the rating for TVTX by listing it as a “Buy.” The predicted price for TVTX in the upcoming period, according to H.C. Wainwright is $30 based on the research report published on June 11, 2025 of the current year 2025.
Citigroup, on the other hand, stated in their research note that they expect to see TVTX reach a price target of $32, previously predicting the price at $35. The rating they have provided for TVTX stocks is “Buy” according to the report published on June 11th, 2025.
TVTX Trading at -12.11% from the 50-Day Moving Average
After a stumble in the market that brought TVTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -41.32% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TVTX starting from Inrig Jula, who sale 815 shares at the price of $14.65 back on Jul 01 ’25. After this action, Inrig Jula now owns 88,787 shares of Travere Therapeutics Inc, valued at $11,940 using the latest closing price.
Cline Christopher R., the CHIEF FINANCIAL OFFICER of Travere Therapeutics Inc, sale 1,784 shares at $21.05 during a trade that took place back on May 05 ’25, which means that Cline Christopher R. is holding 93,126 shares at $37,553 based on the most recent closing price.
Stock Fundamentals for TVTX
Current profitability levels for the company are sitting at:
- -0.82 for the present operating margin
- 0.92 for the gross margin
The net margin for Travere Therapeutics Inc stands at -0.83. The total capital return value is set at -0.61. Equity return is now at value -422.66, with -37.27 for asset returns.
Based on Travere Therapeutics Inc (TVTX), the company’s capital structure generated 0.92 points at debt to capital in total, while cash flow to debt ratio is standing at -0.4. The debt to equity ratio resting at 12.2. The interest coverage ratio of the stock is -19.91.
Currently, EBITDA for the company is -265.77 million with net debt to EBITDA at -2.01. When we switch over and look at the enterprise to sales, we see a ratio of 6.06. The receivables turnover for the company is 7.96for trailing twelve months and the total asset turnover is 0.5. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.05.
Conclusion
To sum up, Travere Therapeutics Inc (TVTX) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
